Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC6001 in Healthy Chinese Adults (Stargardt Disease)
NCT07417566Phase 1Recruiting
- Sponsor
- HeraNova Lifesciences
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DC6001 in Stargardt disease (STGD), sponsored by HeraNova Lifesciences. Primary endpoint: Number of Participants With Adverse Events at 28 days. Started Jan 2026; status: recruiting.
02
Drugs
DC6001
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT07417566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07417566.